Rating Change
Barclays analysts initiated coverage on SAB Biotherapeutics, Inc. (NASDAQ:SABS) with a Overweight rating on June 24, 2026.
new coverageNASDAQ:SABS
Barclays Initiates Coverage on SAB Biotherapeutics, Inc. (SABS) with Overweight
Rating Change Barclays analysts initiated coverage on SAB Biotherapeutics, Inc. (NASDAQ:SABS) with a Overweight rating on June 24, 2026. Market Context SAB Biotherapeutics, Inc.
Market Context
SAB Biotherapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $3.84 with a market capitalization of $34.3M.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for SAB Biotherapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for SAB Biotherapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 24, 2026 | Barclays | Overweight | N/A |
| Jun 17, 2026 | Chardan Capital | Buy | N/A |
| Jun 15, 2026 | Leerink Partners | Outperform | N/A |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 22, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View SABS Stock Page
Frequently Asked Questions
What does a Overweight rating mean for SABS?
A Overweight rating from Barclays reflects the analyst's outlook on SAB Biotherapeutics, Inc. (NASDAQ:SABS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SABS forecast page.